Literature DB >> 23690550

It is possible: availability of lymphedema case management in each health facility in Togo. Program description, evaluation, and lessons learned.

Els Mathieu1, Ameyo M Dorkenoo, Michael Datagni, Paul T Cantey, Kodjo Morgah, Kira Harvey, Joshua Ziperstein, Naomi Drexler, Gina Chapleau, Yao Sodahlon.   

Abstract

Lymphatic filariasis (LF) is a vector-borne parasitic disease that can clinically manifest as disabling lymphedema. Although the LF elimination program aims to reduce disability and to interrupt transmission, there has been a scarcity of disease morbidity management programs, particularly on a national scale. This report describes the implementation of the first nationwide LF lymphedema management program. The program, which was initiated in Togo in 2007, focuses on patient behavioral change. Its goal is two-fold: to achieve a sustainable program on a national-scale, and to serve as a model for other countries. The program has five major components: 1) train at least one health staff in lymphedema care in each health facility in Togo; 2) inform people with a swollen leg that care is available at their dispensary; 3) train patients on self-care; 4) provide a support system to motivate patients to continue self-care by training community health workers or family members and providing in home follow-up; and 5) integrate lymphedema management into the curriculum for medical staff. The program achieved the inclusion of lymphedema management in the routine healthcare package. The evaluation after three years estimated that 79% of persons with a swollen leg in Togo were enrolled in the program. The adherence rate to the proposed World Health Organization treatment of washing, exercise, and leg elevation was more than 70% after three years of the program, resulting in a stabilization of the lymphedema stage and a slight decrease in reported acute attacks among program participants. Health staff and patients consider the program successful in reaching and educating the patients. After the external funding ended, the morbidity management program is maintained through routine Ministry of Health activities.

Entities:  

Mesh:

Year:  2013        PMID: 23690550      PMCID: PMC3748474          DOI: 10.4269/ajtmh.12-0453

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  20 in total

Review 1.  Controlling morbidity and interrupting transmission: twin pillars of lymphatic filariasis elimination.

Authors:  A R Seim; G Dreyer; D G Addiss
Journal:  Rev Soc Bras Med Trop       Date:  1999 May-Jun       Impact factor: 1.581

2.  Efficacy and sustainability of a footcare programme in preventing acute attacks of adenolymphangitis in Brugian filariasis.

Authors:  T K Suma; R K Shenoy; V Kumaraswami
Journal:  Trop Med Int Health       Date:  2002-09       Impact factor: 2.622

3.  A survey of treatment practices and burden of lymphoedema in Togo.

Authors:  Stephanie A Richard; Els Mathieu; David G Addiss; Yao K Sodahlon
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-11-16       Impact factor: 2.184

4.  Lymphatic filariasis: progress of disability prevention activities.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2004-11-19

Review 5.  Progress towards eliminating lymphatic filariasis in Zanzibar: a model programme.

Authors:  Khalfan A Mohammed; David H Molyneux; Marco Albonico; Francesco Rio
Journal:  Trends Parasitol       Date:  2006-05-19

6.  Scarification as a risk factor for rapid progression of filarial elephantiasis.

Authors:  S K Dunyo; C K Ahorlu; P E Simonsen
Journal:  Trans R Soc Trop Med Hyg       Date:  1997 Jul-Aug       Impact factor: 2.184

7.  Health-related stigma among women with lymphatic filariasis from the Dominican Republic and Ghana.

Authors:  Bobbie Person; L Kay Bartholomew; Margaret Gyapong; David G Addiss; Bart van den Borne
Journal:  Soc Sci Med       Date:  2008-11-05       Impact factor: 4.634

8.  Use and limitations of malaria rapid diagnostic testing by community health workers in war-torn Democratic Republic of Congo.

Authors:  Michael Hawkes; Jean Paul Katsuva; Claude K Masumbuko
Journal:  Malar J       Date:  2009-12-23       Impact factor: 2.979

Review 9.  Lymphatic filariasis and the women of India.

Authors:  L Bandyopadhyay
Journal:  Soc Sci Med       Date:  1996-05       Impact factor: 4.634

10.  Neglected patients with a neglected disease? A qualitative study of lymphatic filariasis.

Authors:  Myrtle Perera; Margaret Whitehead; David Molyneux; Mirani Weerasooriya; Godfrey Gunatilleke
Journal:  PLoS Negl Trop Dis       Date:  2007-11-21
View more
  6 in total

1.  Ongoing surveillance for lymphatic filariasis in Togo: assessment of alternatives and nationwide reassessment of transmission status.

Authors:  Philip J Budge; Ameyo M Dorkenoo; Yao K Sodahlon; Omofolarin B Fasuyi; Els Mathieu
Journal:  Am J Trop Med Hyg       Date:  2013-11-04       Impact factor: 2.345

2.  Economic Costs and Benefits of Community-Based Lymphedema-Management Programs for Lymphatic Filariasis in India.

Authors:  Larry Sawers; Eileen Stillwaggon
Journal:  Am J Trop Med Hyg       Date:  2020-07       Impact factor: 2.345

Review 3.  Self-Care for Management of Secondary Lymphedema: A Systematic Review.

Authors:  Janet Douglass; Patricia Graves; Susan Gordon
Journal:  PLoS Negl Trop Dis       Date:  2016-06-08

Review 4.  The Role of Nurses and Community Health Workers in Confronting Neglected Tropical Diseases in Sub-Saharan Africa: A Systematic Review.

Authors:  Andrew G Corley; Clifton P Thornton; Nancy E Glass
Journal:  PLoS Negl Trop Dis       Date:  2016-09-15

Review 5.  The Effect of Hygiene-Based Lymphedema Management in Lymphatic Filariasis-Endemic Areas: A Systematic Review and Meta-analysis.

Authors:  Meredith E Stocks; Matthew C Freeman; David G Addiss
Journal:  PLoS Negl Trop Dis       Date:  2015-10-23

6.  Economic Costs and Benefits of a Community-Based Lymphedema Management Program for Lymphatic Filariasis in Odisha State, India.

Authors:  Eileen Stillwaggon; Larry Sawers; Jonathan Rout; David Addiss; LeAnne Fox
Journal:  Am J Trop Med Hyg       Date:  2016-08-29       Impact factor: 2.345

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.